Forzinity: Dosage, Uses | Elamipretide | Para IV Filing

Forzinity

Forzinity is a mitochondrial-targeted therapy for Barth syndrome in patients weighing 30 kg or more. It stabilizes mitochondrial function to improve energy production and muscle strength, administered via subcutaneous injection.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Elamipretide
Innovator :

STEALTH BIOTHERAPEUTICS INC
Approval Date :

19-Sep-25
NCE-1 Date :

19-Sep-29
NCE Date :

19-Sep-30
Dosage Form :

Subcutaneous Solution
Strength :

EQ 280MG BASE/3.5ML (EQ 80MG BASE/ML)
Therapeutic Category :

Mitochondrial Dysfunction Agent
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2025 :

NA
2026 :

NA
2027 :

NA
2028 :

NA
2029 :

NA
2030 :

NA
2031 :

NA

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Forzinity

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?